Welcome to our dedicated page for Viking Therapeutics SEC filings (Ticker: VKTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Viking Therapeutics, Inc. (NASDAQ: VKTX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as it advances a clinical-stage pipeline in metabolic and endocrine disorders. Viking’s Form 8-K filings, for example, report material events such as quarterly financial results and top-line clinical data from trials of VK2735, the company’s dual GLP-1/GIP receptor agonist being developed for obesity and other metabolic conditions. One 8-K references a press release announcing financial results and a corporate update, while another notes top-line Phase 2 results from the oral tablet formulation of VK2735.
Through SEC reports such as 8-K, investors can track how Viking communicates progress in its Phase 3 VANQUISH program for subcutaneous VK2735, Phase 2 and earlier-stage work on oral VK2735, and development of VK2809 for lipid and liver disorders and VK0214 for X-linked adrenoleukodystrophy. These filings complement press releases that describe statistically significant weight loss outcomes, safety and tolerability profiles, and achievement of primary and secondary endpoints in key studies.
On Stock Titan, Viking’s SEC filings are paired with AI-powered tools that summarize and explain the contents of lengthy documents. Investors can quickly understand the implications of quarterly updates, clinical data disclosures, and other material events without reading every line of each filing. Real-time updates from EDGAR ensure that new 8-Ks and other forms appear promptly, while AI-generated highlights help users focus on items such as clinical trial milestones, pipeline strategy, and financial condition as reported by Viking Therapeutics in its official SEC submissions.
Viking Therapeutics (VKTX) reported insider activity by a director on 10/27/2025. The director exercised stock options for 60,000 shares in total—16,000 at an exercise price of $4.48, 22,000 at $5.80, and 22,000 at $4.88.
On the same date, the director sold 60,000 shares at a $35.5713 weighted-average price, with sales occurring between $35.02 and $35.94. Following these transactions, the director beneficially owned 30,000 shares directly.
Option origins and terms disclosed include grants dated 01/02/2019 (expiring 01/02/2028), 01/04/2022 (expiring 01/04/2031), and 01/03/2023 (expiring 01/03/2032), each corresponding to the exercised amounts listed above.
Viking Therapeutics (VKTX) President & CEO and director reported equity activity on Form 4. On 10/27/2025, 70,084 shares of common stock were acquired at $0 upon vesting of performance RSUs tied to non-financial goals. On 10/28/2025, 38,989 shares were sold at a $35.0079 weighted average solely to satisfy tax withholding, with trades ranging $34.66–$35.48. Following the transactions, direct beneficial ownership stands at 2,419,109 shares.
Viking Therapeutics (VKTX) reported a Form 4 for its Chief Financial Officer. On 10/27/2025, the CFO acquired 11,117 shares of common stock at $0 upon vesting of performance RSUs tied to non-financial goals. On 10/28/2025, 6,185 shares were sold at a weighted average price of $35.0009 to satisfy tax withholding related to that vesting.
Following these transactions, the CFO directly holds 173,592 shares. Shares briefly stood at 179,777 after the vesting before the tax-related sale.
Viking Therapeutics (VKTX) filed its Q3 2025 report, showing higher R&D as programs advanced and a wider loss. For the quarter, net loss was $90.8 million, or $0.81 per share, driven by research and development expense of $89.9 million and general and administrative expense of $8.6 million. There was no revenue.
Liquidity remained strong with cash and cash equivalents of $100.4 million and short‑term investments of $614.2 million as of September 30, 2025. For the nine months, the company used $193.4 million in operating cash. Stockholders’ equity was $713.0 million.
Capital markets tools are in place: an S‑3 shelf effective July 2023, ATM capacity remaining up to $151.9 million, and a $250.0 million repurchase program authorized in February 2025 (no repurchases in Q3). The March 2024 offering provided $597.1 million net proceeds. Shares outstanding were 113,036,344 as of October 15, 2025.
Operationally, Viking entered multi‑year manufacturing agreements for VK2735 with prepayments from 2025 to 2028 credited against future orders. A subsequent lease amendment expands headquarters space, with $63,000 monthly base rent starting on the later of substantial completion or April 1, 2026.
Viking Therapeutics (VKTX) furnished an 8-K announcing it issued a press release reporting financial results for the third quarter ended September 30, 2025 and providing a corporate update. The press release is included as Exhibit 99.1. The company notes that the information under Item 2.02 is furnished, not filed, under the Exchange Act.
Viking Therapeutics, Inc. filed a current report to highlight that, on August 19, 2025, it issued a press release announcing top-line results from its Phase 2 clinical trial of the oral tablet formulation of VK2735. The company furnished this press release as Exhibit 99.1 and clarified that the information provided under the Regulation FD disclosure section is being furnished rather than filed for liability purposes under securities laws.